Treating chromoblastomycosis with systemic antifungals.
Chromoblastomycosis is a subcutaneous mycosis for which there is no treatment of choice but rather, several treatment options, with low cure rates and many relapses. The choice of treatment should consider several conditions, such as the causal agent (the most common one being Fonsecaea pedrosoi ), extension of the lesions, clinical topography and health status of the patient. Most oral and systemic antifungals have been used; the best results have been obtained with itraconazole and terbinafine at high doses, for a mean of 6 - 12 months. In extensive and refractory cases, chemotherapy with oral antifungals may be associated with thermotherapy (local heat and/or cryosurgery). Limited or early cases may be managed with surgical methods, always associated with oral antifungal agents. It is important to determine the in vitro sensitivity of the major causal agents to the various drugs, by estimating the minimum inhibitory concentration, as well as drug tolerability and drug interactions.
Bonifaz
Alexandro
A
Dermatology Service & Mycology Department, General Hospital of Mexico, Mexico City, Mexico. bonyalx@servidor.unam.mx
Paredes-Solís
Vanessa
V
Saúl
Amado
A
D000284:Administration, Oral; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002862:Chromoblastomycosis / Q000209:etiology / Q000601:surgery / Q000628:therapy*; D003452:Cryosurgery; D006801:Humans; D006979:Hyperthermia, Induced; D008800:Mexico
D000935:Antifungal Agents